204 related articles for article (PubMed ID: 33198953)
1. Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review.
Supe S; Upadhya A; Singh K
Exp Eye Res; 2021 Jan; 202():108329. PubMed ID: 33198953
[TBL] [Abstract][Full Text] [Related]
2. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF.
Jiang J; Xia XB; Xu HZ; Xiong Y; Song WT; Xiong SQ; Li Y
J Cell Physiol; 2009 Jan; 218(1):66-74. PubMed ID: 18767037
[TBL] [Abstract][Full Text] [Related]
4. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.
Guzman-Aranguez A; Loma P; Pintor J
Br J Pharmacol; 2013 Oct; 170(4):730-47. PubMed ID: 23937539
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
6. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update.
Lin FL; Wang PY; Chuang YF; Wang JH; Wong VHY; Bui BV; Liu GS
Mol Ther; 2020 Oct; 28(10):2120-2138. PubMed ID: 32649860
[TBL] [Abstract][Full Text] [Related]
8. Small interference RNA targeting vascular endothelial growth factor gene effectively attenuates retinal neovascularization in mice model.
Kong YC; Sun B; Zhao KX; Han M; Wang YC
Chin Med J (Engl); 2013; 126(8):1440-4. PubMed ID: 23595374
[TBL] [Abstract][Full Text] [Related]
9. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
[TBL] [Abstract][Full Text] [Related]
10. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Reich SJ; Fosnot J; Kuroki A; Tang W; Yang X; Maguire AM; Bennett J; Tolentino MJ
Mol Vis; 2003 May; 9():210-6. PubMed ID: 12789138
[TBL] [Abstract][Full Text] [Related]
11. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems.
Rezaee M; Oskuee RK; Nassirli H; Malaekeh-Nikouei B
J Control Release; 2016 Aug; 236():1-14. PubMed ID: 27317365
[TBL] [Abstract][Full Text] [Related]
12. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat.
Amadio M; Pascale A; Cupri S; Pignatello R; Osera C; D Agata V; D Amico AG; Leggio GM; Ruozi B; Govoni S; Drago F; Bucolo C
Pharmacol Res; 2016 Sep; 111():713-720. PubMed ID: 27475885
[TBL] [Abstract][Full Text] [Related]
13. Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes.
Lajunen T; Hisazumi K; Kanazawa T; Okada H; Seta Y; Yliperttula M; Urtti A; Takashima Y
Eur J Pharm Sci; 2014 Oct; 62():23-32. PubMed ID: 24810393
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of retinal and choroidal vascular diseases.
Campochiaro PA
Prog Retin Eye Res; 2015 Nov; 49():67-81. PubMed ID: 26113211
[TBL] [Abstract][Full Text] [Related]
15. Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy.
Supe S; Upadhya A; Tripathi S; Dighe V; Singh K
Drug Deliv Transl Res; 2023 Jun; 13(6):1675-1698. PubMed ID: 36630075
[TBL] [Abstract][Full Text] [Related]
16. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.
Kleinman ME; Yamada K; Takeda A; Chandrasekaran V; Nozaki M; Baffi JZ; Albuquerque RJ; Yamasaki S; Itaya M; Pan Y; Appukuttan B; Gibbs D; Yang Z; Karikó K; Ambati BK; Wilgus TA; DiPietro LA; Sakurai E; Zhang K; Smith JR; Taylor EW; Ambati J
Nature; 2008 Apr; 452(7187):591-7. PubMed ID: 18368052
[TBL] [Abstract][Full Text] [Related]
17. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
18. Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells.
Xu L; Shen W; Wang B; Wang X; Liu G; Tao Y; Qi R
Curr Drug Deliv; 2016; 13(4):590-9. PubMed ID: 26279119
[TBL] [Abstract][Full Text] [Related]
19. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
